Purpose: Drug-eluting device and covered stent have become the mainstream of endovascular therapy for femoropopliteal lesions. Although there have been many reports on the primary patency of each device, there are few detailed data on restenosis and reocclusion. Materials and methods: This was a physician-initiated, multicenter, retrospective study. From seven institutes, 3,635 femoropopliteal cases were enrolled in this study. Among them, we studied 2,786 cases treated with drug-eluting stent (DES), drug-coated balloon (DCB), covered stent (CS), and bare nitinol stent (BNS). Results: The lesion background for each device was different, with mean lesion lengths of 140 (80-220) mm for BNS, 250 (180-300) mm for CS, 200 (100-260) mm for DES, and 123 (60-216) mm for DCB (p<0.001). Primary patency at two years was 62% for BNS, 75% for CS, 74% for DES, and 65% for DCB. The timing of restenosis and reocclusion was also different for each device. Peak restenosis timing was six to nine months for BNS and DCB and 12-15 months for CS and DES. The timing of reocclusion was six to nine months for BNS and DES, three to six months for CS, and zero to three months for DCB. Conclusions: Not only was the primary patency for each device different, but the timing of restenosis and reocclusion for each device was also different.
Suzuki et al. (Sun,) studied this question.